Abstract . We studied two plasma biomarkers in 67 patients with ovarian cancer who had surgery between 1990 and' 1992 . Lipid associated sialic acid in plasma (LASA-P) was assayed by biochemical extraction and p artition . DM/70 K was detected with the monoclonal antibody NB 12123 . We found a highly significant correlation between these two markers (p < 0 .0001) . Neither marker was associated with age or tumor stage or grade . We also studied two tumor markers, Epidermal Growth Factor Receptor (EGFR) and DNA Index (DI) . EGFR and DI were also not related to age of patient, tumor stage, or tumor grade, nor were they related to LASA-P or DM/70K . However, EGFR and DI were positively correlated with each other (p = 0 .04), suggesting that tumor EGFR may be associated with poor survival .
Introduction
There have been numerous reports of the existence and potential clinical value of human tumor markers (1) . But many markers do not have the sensitivity or specificity needed for a cancer diagnostic screening test . Also, many markers are elevated in several malignancies and benign conditions . In ovarian cancer, the circulating plasma markers CA 125, Lipid Associated Sialic Acid in Plasma (LASA-P), CA 19-9, and CEA have been studied (2) . After second look surgery, the finding of two elevated markers, one month or more apart in patients clinically free of disease, was strongly suggestive of recurrence . Another circulating plasma marker, DM/70K, is elevated in 70% of patients with ovarian cancer (3) . High levels of DM/70K are also associated with other gynecologic malignancies, as well as carcinoma of the lung and breast . Markers in the tumors themselves are of interest (4) and Epidermal Growth Factor Receptor (EGFR) (5) have both been evaluated . We report here on our study of LASA-P, DM/70K, DI and EGFR in ovarian cancer patients .
Patients and methods
We studied 67 patients with ovarian cancer who had surgery between 1990 and 1992 . All tumors were epithelial ovarian carcinomas except for one involving the fallopian tube . Plasma specimens to be assayed for LASA-P and DM/70K were collected in tubes containing ethylenediamine tetra acetic acid (EDTA) and frozen until tested . LASA-P was assayed by biochemical extraction and partition (6) . DM/70K was detected with the monoclonal antibody N13 12123 (3) . Fresh frozen tumor specimens were analyzed by flow cytometry to assess DI (4) . EGFR was measured in the same specimens by radioimmunoassay (7) . Dianon Systems, Stratford, Connecticut, performed all assays .
Results
We could find no relationship between LASA-P or DM/70K and tumor stage, tumor grade or age of the patient . However, we did find a highly significant correlation between DM/70K and LASA-P levels (Fig . 1) . Tumor EGFR and tumor DI were also not related to age of patient, tumor stage, or tumor grade, nor were they related to LASA-P or DM/70K . However, EGFR and DI were positively correlated with each other (Fig . 2) .
Discussion
Tumor DI is a useful prognostic factor in ovarian cancer . Patients with diploid or near diploid tumors (DI < 1 .25) survived significantly longer than those with aneuploid tumor (DI > 1 .25) (4) .
Tumor EGFR is associated with poor prognosis in breast cancer (7) . In ovarian cancer, the role of EGFR is less certain. One study associated EGFR with improved response to chemotherapy and increased overall survival (8) ; another investigation linked EGFR in advanced ovarian cancer with poor prognosis (9) . Our finding of a positive correlation of EGFR with DI suggests that tumor EGFR should be associated with poor prognosis . Further studies are needed to clarify this finding. DM/70 K is one of the more promising new circulating tumor markers for ovarian epithelial carcinoma . Unlike CA-125, which is only rarely elevated in mucinous ovarian malignancies, DM/70K seems to be a marker for all types of epithelial ovarian carcinomas, regardless of histologic type or degree of differentiation . In addition, circulating DM/70K levels are high in patients with all stages of ovarian cancer, including more than half of those with early stage disease . Thus, DM/70K might be useful for early detection of ovarian cancer, as well as for monitoring patients with the disease (1) . However, DM/70K is still designated as being for investigational use only . LASA-P is a biomarker useful in a wide range of malignancies . It reflects alteration in the surface membrane of malignant cells . The assay for LASA-P measures gangliosides and glycoproteins 1 .5 1 .7 1.9 2 .1 2.3 2 .5 Tumor DNA Index found in the lipid fraction of plasma . LASA-P is elevated in most patients with disseminated ovarian carcinoma and normal in almost all patients with benign ovarian tumors . LASA-P measurements correlate well with serum CA-125 . Moreover, the sensitivity of LASA-P and CA-125, when used together, is higher than when either assay is used alone (2) . Our finding of a strong correlation between LASA-P and DM/70K measurements suggests that the combination of the two assays might be more sensitive than either one alone . This sensitivity might be increased even further with the addition of CA-125 . Although more evaluation is necessary, the use of all three assays could be of more value in early detection and post treatment follow-up of ovarian cancer than the use of one or even two assays in tandem .
